Results 41 to 50 of about 1,580 (184)
, 2021 Mavacamten, a selective inhibitor of cardiac myosin ATPase, which reduces hypercontractility, is the first disease-specific treatement of HCM. In phase 2 trials including persons with HCM without outflow obstruction, a significant reduction in NT-proBNP ...
Magnusson, P., Karason, Kristjan,
core
Experimental Physiology, EarlyView.Abstract Eccentric muscle contractions are essential for locomotion and daily activities. Force during these contractions depends on both cross‐bridge (XB) and non‐cross‐bridge (non‐XB) elements, including titin, with contributions varying by fibre type and contraction velocity.
André Tomalka +3 more
wiley +1 more source
[Mavacamten - the first disease-specific pharmacological treatment of hypertrophic cardiomyopathy]
, 2021 Mavacamten, a selective inhibitor of cardiac myosin ATPase, which reduces hypercontractility, is the first disease-specific treatement of HCM. In phase 2 trials including persons with HCM without outflow obstruction, a significant reduction in NT-proBNP ...
Karason, K, Magnusson, P,
core
Long-term effect of mavacamten in obstructive hypertrophic cardiomyopathy. [PDF]
BACKGROUND AND AIMS: Long-term safety and efficacy of mavacamten in patients with obstructive hypertrophic cardiomyopathy (HCM) are unknown. MAVA-LTE (NCT03723655) is an ongoing, 5-year, open-label extension study designed to evaluate the long-term ...
Wheeler, Matthew +24 more
core +2 more sources
The Journal of Physiology, EarlyView.Abstract figure legend In this study, we used mathematical modelling to explore the effect of diabetes on muscle mechanoenergetics. Our parameterisation of cross‐bridge models using data from non‐diabetic and diabetic human atrial tissues revealed lower values for cross‐bridge stiffness, detachment rates, attachment rates and lower ATP sensitivity in ...
Julia H. Musgrave +4 more
wiley +1 more source
Translating cardiovascular ion channel and Ca2+ signalling mechanisms into therapeutic insights
The Journal of Physiology, EarlyView.Abstract figure legend This white paper integrates mechanistic discoveries across ion channel biology, Ca2+ signalling and multiscale cardiovascular physiology to highlight new opportunities for accelerating research and guiding next‐generation therapies. Printed with permission from ®Anita Impagliazzo Medical Illustration. [Correction added on 2 March
Silvia Marchianò +18 more
wiley +1 more source
British Journal of Clinical Pharmacology, Volume 92, Issue 6, Page 1934-1939, June 2026.Pharmacogenomic (PGx) information has the potential to support the safe and effective use of medicines, yet there is uncertainty about how this information can be best communicated to patients. Summaries of product characteristics (SmPCs) and patient information leaflets (PILs) for all UK‐approved medicines with strong evidence supporting a PGx ...
Parth Narlawar +5 more
wiley +1 more source
Physiological ReportsThe first‐in‐its‐class cardiac drug mavacamten shifts myosin heads towards a structurally inactive position where they lay along the helical tracks of the thick filament.
Michel N. Kuehn +8 more
doaj +1 more source
, 2021 Current pharmacotherapy for hypertrophic cardiomyopathy (HCM) is not disease-specific and has suboptimal efficacy, often necessitating interventional treatment.
Rajtar-Salwa, Renata; Department of Cardiology and Cardiovascular Interventions, University Hospital, Kraków, Poland +5 more
core +1 more source
Journal of Arrhythmia, Volume 42, Issue 3, June 2026.Multicentre retrospective propensity‐score‐matched cohort study (n = 286; 3 centres, Pakistan; 2015‐2023) comparing electrophysiological substrate and 12‐month ablation outcomes in patients with atrial fibrillation and hypertrophic cardiomyopathy (HCM‐AF, red) versus lone atrial fibrillation (Lone AF, green; 1:1 PSM on 14 covariates).
Umair Abrar +7 more
wiley +1 more source